The following two links contain recent publications on construction of a fowlpox vector with multiple antigens:
1- A safety assessment of a fowlpox-vectoredMycoplasma gallisepticum vaccine in chickens
G. Z. Zhang*, 1, R. Zhang*, H. L. Zhao*,†, X. T. Wang*, S. P. Zhang*, X. J. Li*,
C. Z. Qin*, C. M. Lv*, J. X. Zhao* and J. F. Zhou†
Poultry Science (2010) 89 (6): 1301-1306.
doi: 10.3382/ps.2009-00447
ABSTRACT
A recombinant fowlpox virus vaccine expressing key protectiveMycoplasma gallisepticum antigens could facilitate in the prevention both of fowlpox virus and M. gallisepticum infections. Vectormune FP-MG vaccine, a recombinant fowlpox virus expressing both M. gallisepticum40k and mgc genes, was assessed for its safety in 8-wk-old specific-pathogen-free White Leghorn chickens. The vaccine virus was serially passaged 5 times by wing-web inoculation. Based on the postinoculation clinical observation, gross pathological examination of air sacs and peritoneum, genetic stability evaluation, virus shedding and tissue distribution detection, horizontal transmission ability determination, and protection against fowlpox virus challenge, the Vectormune FP-MG vaccine possesses a high level of safety.
2- Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules
Article in BioTechniques 37(1):104-6, 108-11 · August 2004
Abstract
Here we describe plasmid vectors and selection protocols developed to allow the construction of recombinant fowlpox viruses (rFPVs) with up to three insertions of foreign DNA in the viral genome. Transient dominant selection allows the construction of recombinant viruses that do not retain the selection markers and can therefore be used for the insertion of additional genes at other sites in the viral genome. A SYBR Green real-time PCR sequence detection assay was applied to the identification of recombinant viruses from individual plaques, eliminating the need for amplification and hybridization from the transient dominant protocol and resulting in significant savings in time at each round of plaque purification. Dominant selection techniques allow more rapid recombinant virus construction; however, as the markers are retained along with the gene of interest, they can only be used to generate the final recombinant. rFPV vaccines constructed using these techniques have reached preclinical nonhuman primate and phase I human clinical trials in prime/boost vaccination studies as human immunodeficiency virus (HIV) therapeutic andprophylactic vaccines.